Every round on record, with the sources behind each and the investors on them.
A clinical-stage medical technology company advancing Endoscopic Metabolic Restoration for the treatment of Type 2 diabetes
aquaendoscopy.comPleasanton, CA, USAHealthtech
12 sources · checked 2 times, last 9d ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
Relevance Ventures’ release dates its announcement September 23, but Aqua Medical’s own release announces the financing on September 24; the company release wins. The round amount is described only as “multimillion.”
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The dateline identifies Santa Ana, Calif., but does not state that it is Aqua Medical's headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B | n/a | 2026-09-24 | Relevance Ventures | No recent discussion |
12 sources · checked 2 times, last 9d ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 4 of 12 sources Relevance Ventures’ release dates its announcement September 23, but Aqua Medical’s own release announces the financing on September 24; the company release wins. The round amount is described only as “multimillion.” | ||||
Aqua Medical is a clinical-stage medical technology company developing a minimally invasive, through-the-scope radiofrequency vapor ablation procedure (PIMA) to treat Type 2 diabetes.
Type 2 diabetes affects roughly 589 million people globally and drives more than $1 trillion in annual healthcare expenditures, while care has centered on pharmaceutical management and invasive surgery. Aqua is betting that a minimally invasive, no-fluoroscopy, through-the-endoscope PIMA procedure can improve metabolic outcomes; its 2026 Series B will fund completion of RESTORE-1 and preparation for a pivotal trial after 66 patients were treated outside the United States and four U.S. procedures, although the diabetes use remains investigational.
Checked against 10 sources on Sep 24
| Series A Series A-3 [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $8.2M | ~ 2020-09 | ShangBay Capital | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The dateline identifies Santa Ana, Calif., but does not state that it is Aqua Medical's headquarters. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: prnewswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||